Bionano to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
Bionano Genomics (Nasdaq: BNGO) has announced that its CEO, Erik Holmlin, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9th, 2024. The presentation is scheduled for 11:00 a.m. to 11:30 a.m. ET.
Investors and interested parties can register for the webcast through a provided link. A replay of the session will be available on the Bionano website at ir.bionano.com for at least 30 days following the conference, allowing those unable to attend live to catch up on the company's latest updates and strategic insights.
This presentation at a major investment conference suggests that Bionano Genomics is actively engaging with the investment community, potentially signaling important company developments or seeking to raise its profile among investors.
Bionano Genomics (Nasdaq: BNGO) ha annunciato che il suo CEO, Erik Holmlin, presenterà al 26° Annual Global Investment Conference di H.C. Wainwright il 9 settembre 2024. La presentazione è programmata dalle 11:00 alle 11:30 ET.
Gli investitori e le parti interessate possono registrarsi per la webcast tramite un link fornito. Una registrazione della sessione sarà disponibile sul sito web di Bionano all'indirizzo ir.bionano.com per almeno 30 giorni dopo la conferenza, permettendo a coloro che non possono partecipare dal vivo di recuperare gli aggiornamenti più recenti e le intuizioni strategiche dell'azienda.
Questa presentazione in una importante conferenza di investimenti suggerisce che Bionano Genomics stia attivamente coinvolgendo la comunità degli investitori, segnalando potenzialmente sviluppi significativi dell'azienda o cercando di aumentare la sua visibilità tra gli investitori.
Bionano Genomics (Nasdaq: BNGO) ha anunciado que su CEO, Erik Holmlin, presentará en la 26ª Conferencia Anual de Inversiones Globales de H.C. Wainwright el 9 de septiembre de 2024. La presentación está programada de 11:00 a.m. a 11:30 a.m. ET.
Los inversores y las partes interesadas pueden registrarse para el webcast a través de un enlace proporcionado. Una repetición de la sesión estará disponible en el sito web de Bionano en ir.bionano.com durante al menos 30 días después de la conferencia, permitiendo que aquellos que no puedan asistir en vivo se pongan al día con las actualizaciones más recientes y las ideas estratégicas de la empresa.
Esta presentación en una importante conferencia de inversiones sugiere que Bionano Genomics está activamente involucrando a la comunidad de inversores, lo que sugiere posiblemente desarrollos importantes para la empresa o tratando de elevar su perfil entre los inversores.
Bionano Genomics (Nasdaq: BNGO)는 CEO인 Erik Holmlin이 H.C. Wainwright 제26회 국제 투자 회의에서 2024년 9월 9일에 발표할 것이라고 발표했습니다. 발표는 오전 11시부터 오전 11시 30분 ET까지 예정되어 있습니다.
투자자 및 관심 있는 개인은 제공된 링크를 통해 웨비나에 등록할 수 있습니다. 세션의 재방송은 Bionano 웹사이트인 ir.bionano.com에서 회의 종료 후 최소 30일 동안 제공되며, 실시간으로 참석할 수 없는 사람들은 회사의 최신 업데이트 및 전략적 통찰력을 확인할 수 있습니다.
이 주요 투자 회의에서의 발표는 Bionano Genomics가 투자 커뮤니티에 적극적으로 참여하고 있음을 나타내며, 이는 회사의 중요한 발전을 알리거나 투자자들 사이에서 자신의 프로필을 높이려는 신호일 수 있습니다.
Bionano Genomics (Nasdaq: BNGO) a annoncé que son PDG, Erik Holmlin, présentera lors de la 26e Conférence Annuelle Mondiale d'Investissement H.C. Wainwright le 9 septembre 2024. La présentation est prévue de 11h00 à 11h30 ET.
Les investisseurs et les parties intéressées peuvent s'inscrire pour le webinaire via un lien fourni. Une rediffusion de la session sera disponible sur le site Web de Bionano à l'adresse ir.bionano.com pendant au moins 30 jours après la conférence, permettant à ceux qui ne peuvent pas y assister en direct de se mettre à jour sur les dernières nouvelles de l'entreprise et ses perspectives stratégiques.
Cette présentation lors d'une importante conférence d'investisseurs suggère que Bionano Genomics s'engage activement avec la communauté des investisseurs, ce qui pourrait signaler des développements importants pour l'entreprise ou chercher à accroître son profil auprès des investisseurs.
Bionano Genomics (Nasdaq: BNGO) hat bekannt gegeben, dass der CEO Erik Holmlin am 9. September 2024 auf der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright präsentieren wird. Die Präsentation ist von 11:00 bis 11:30 Uhr ET angesetzt.
Investoren und Interessierte können sich über einen bereitgestellten Link zur Webübertragung anmelden. Eine Aufzeichnung der Sitzung wird auf der Website von Bionano unter ir.bionano.com für mindestens 30 Tage nach der Konferenz verfügbar sein und ermöglicht es Personen, die nicht live teilnehmen können, die neuesten Updates und strategischen Einblicke des Unternehmens nachzuholen.
Diese Präsentation auf einer bedeutenden Investorenkonferenz deutet darauf hin, dass Bionano Genomics aktiv mit der Investoren-Community kommuniziert, was möglicherweise auf wichtige Entwicklungen im Unternehmen hinweist oder darauf abzielt, das Profil bei den Investoren zu erhöhen.
- None.
- None.
SAN DIEGO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9th, 2024.
Conference & Webcast Details
| Date: | September 9, 2024 |
| Time: | 11:00 a.m. to 11:30 a.m. ET |
| Presenter: | Erik Holmlin, PhD, CEO of Bionano |
| Webcast: | Link to Register |
A replay / recording of the session will be available following the conference through the Bionano website at ir.bionano.com for at least 30 days.
About Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services. For more information, visit bionano.com and bionanolaboratories.com.
Unless specifically noted otherwise, Bionano’s OGM products are for research use only and not for use in diagnostic procedures.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com
Investor Relations:
David Holmes
Gilmartin Group
+1 (858) 888-7625
IR@bionano.com
FAQ
When is Bionano Genomics (BNGO) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for Bionano Genomics (BNGO) at the investment conference?
How can investors access Bionano Genomics' (BNGO) presentation at the H.C. Wainwright conference?
What is the significance of Bionano Genomics (BNGO) presenting at this investment conference?
